Literature DB >> 27879294

CXCR2 is involved in pulmonary intravascular macrophage accumulation and angiogenesis in a rat model of hepatopulmonary syndrome.

Xujiong Li1, Yunxia Chen2, Yongli Chang3, Shufen Li3, Zhongfu Zhao4, Huiying Zhang5.   

Abstract

Hepatopulmonary syndrome (HPS) is a lung complication in various liver diseases, with high incidence, poor prognosis and no effective non-surgical treatments in patients with hepatocirrhosis. Therefore, assessing HPS pathogenesis to explore proper therapy strategies is clinically relevant. In the present study, male Sprague-Dawley rats underwent sham operation or common bile duct ligation (CBDL). Two weeks post-surgery, the following groups were set up for 2 weeks of treatment: sham + normal saline, CBDL + CXCR2 antagonist SB225002, CBDL + tumour necrosis factor α (TNF-α) antagonist PTX and CBDL + normal saline groups. Liver and lung tissues were collected after mean arterial pressure (MAP) and portal venous pressure (PVP) measurements. Haematoxylin and eosin (H&E) staining (lung) and Masson staining (liver) were performed for pathological analyses. Finally, pulmonary tissue RNA and total protein were assessed for target effectors. The mRNA and protein levels of CXCR2 were significantly increased in the pulmonary tissue of CBDL rats. What's more, CXCR2 inhibition by SB225002 reduced the expression of CD68 and von Willebrand factor (vWf) in CBDL rats. Importantly, CXCR2 inhibition suppressed the activation of Akt and extracellular signal-regulated kinase (ERK) in CBDL rats. Antagonization of TNF-α with PTX down-regulated the expression of CXCR2. During HPS pathogenesis in rats, CXCR2 might be involved in the accumulation of pulmonary intravascular macrophages and angiogenesis, possibly by activating Akt and ERK, with additional regulation by TNF-α that enhanced pulmonary angiogenesis by directly acting on the pulmonary tissue. Finally, the present study may provide novel targets for the treatment of HPS.
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  CXCR2; angiogenesis; hepatopulmonary syndrome

Mesh:

Substances:

Year:  2016        PMID: 27879294     DOI: 10.1042/CS20160593

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

2.  Hepatocyte-derived exosomal MiR-194 activates PMVECs and promotes angiogenesis in hepatopulmonary syndrome.

Authors:  Lin Chen; Yi Han; Yujie Li; Bing Chen; Xuehong Bai; Karine Belguise; Xiaobo Wang; Yang Chen; Bin Yi; Kaizhi Lu
Journal:  Cell Death Dis       Date:  2019-11-07       Impact factor: 8.469

3.  Better detoxifying effect of ripe forsythiae fructus over green forsythiae fructus and the potential mechanisms involving bile acids metabolism and gut microbiota.

Authors:  Tao Wang; Xu-Jiong Li; Ling-Hao Qin; Xue Liang; Huan-Huan Xue; Jing Guo; Shi-Fei Li; Li-Wei Zhang
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

Review 4.  Hepatopulmonary syndrome.

Authors:  Sarah Raevens; Maxine Boret; Michael B Fallon
Journal:  JHEP Rep       Date:  2022-07-04

5.  CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.

Authors:  Sipei Nie; Yicong Wan; Hui Wang; Jinhui Liu; Jing Yang; Rui Sun; Huangyang Meng; Xiaolin Ma; Yi Jiang; Wenjun Cheng
Journal:  J Ovarian Res       Date:  2021-09-03       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.